Viridian Therapeutics, Inc. Common Stock (VRDN) Stock
Key stats
- Market cap
- $2.79B
- Price / Earnings ratio
- -7.2x
- EPS (TTM)
- -$3.39
- Volume
- Loading
- 52-week high
- $34.29
- 52-week low
- $13.18
- Next earnings report
- 4 Nov 2026
Source: third-party data provider, as of November 3, 2026
Compare with VRDN
Recent news

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
VRDN

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
VRDN

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
VRDN

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
VRDN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 72.25
- MACD 12/26/9
- 1.16
- EMA 9 of MACD
- 0.61
- MACD histogram
- 0.56
- SMA 50
- $21.68
- Price above SMA 50
- EMA 50
- $21.54
- Price above EMA 50
- SMA 200
- $21.72
- Price above SMA 200
- EMA 200
- $23.05
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 2, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.92 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
VRDN

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
VRDN

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
VRDN

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
VRDN

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
VRDN

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
VRDN

Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
VRDN

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
VRDN

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
VRDN

How This Amgen Rival, Up 30%, Plans To Shake Its Grip In Thyroid Eye Disease
How This Amgen Rival, Up 30%, Plans To Shake Its Grip In Thyroid Eye Disease
VRDN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Viridian Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen F. Mahoney J.D., MBA | CEO, President & Director | 1971 |
| Dr. Eric N. Olson Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | — |
| Mr. Seth Harmon | Chief Financial Officer | 1981 |
| Mr. Thomas W. Beetham J.D., MBA | Chief Operating Officer | 1970 |
| Ms. Jennifer Tousignant J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Dr. Radhika Tripuraneni M.D., M.P.H. | Chief Medical Officer | 1980 |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder & Member of the Scientific Advisory Board | 1945 |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder & Scientific Advisory Board Member | 1940 |
| Mr. Vahe Bedian Ph.D. | Co-Founder & Scientific Advisor | — |
| Ms. Melissa Manno | Chief Human Resources Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 3, 2026
Technical indicators
- RSI 14
- 72.25
- MACD 12/26/9
- 1.16
- EMA 9 of MACD
- 0.61
- MACD histogram
- 0.56
- SMA 50
- $21.68
- Price above SMA 50
- EMA 50
- $21.54
- Price above EMA 50
- SMA 200
- $21.72
- Price above SMA 200
- EMA 200
- $23.05
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 2, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $38.00
- Average
- $38.50
- High
- $39.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +6.4 | +7.2 | ||||||||||
| 2022 | -3.1 | -7.3 | +4.8 | -26.3 | -5.6 | -4.7 | +23.7 | +63.5 | -3.3 | -4.2 | +27.9 | +12.2 |
| 2023 | +28.1 | -12.2 | -23.0 | +10.2 | -16.8 | -2.9 | -24.0 | -2.6 | -19.7 | -14.4 | +32.9 | +26.5 |
| 2024 | -13.9 | -6.4 | -12.0 | -23.2 | -13.5 | +8.4 | +27.6 | -9.8 | +57.2 | -8.6 | -3.3 | -8.7 |
| 2025 | -1.9 | -19.5 | -6.5 | +7.9 | +1.3 | +0.1 | +21.1 | +5.6 | +12.7 | +11.1 | +38.1 | -1.0 |
| 2026 | +7.6 | -11.5 | -35.3 | -29.6 | +31.3 | +8.3 | +2.4 | +19.9 | -10.6 | +29.9 |



